The Optimizer Smart was FDA approved in March 2019. Key Randomized Clinical Trials FIX-HF 4: https://t.co/xwhskhvMEx FIX-HF 5: https://t.co/dBHI79Luz2 FIX-HF 5C: https://t.co/CCI1u0C5ib https://t.co/LRaWARSXLB
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation https://t.co/iQNMbgBoud
@FZores @f_mouquet @CNCFCardio @jcldib @GiuseppeGalati_ @CCF_cardio @ShelleyZieroth @PushpaShivaram @purviparwani @HeartOTXHeartMD @SilCastelletti CCM Cardiac contractility modulation. (je comprends pas le mécanisme). - RCT 2011: IC FEVG<35% ❌ pour prim
Device now approved by FDA: A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation -https://t.co/h8FFANXwlN
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation https://t.co/iQNMbgBoud
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation https://t.co/iQNMbgBoud
RT @coconnormd: A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation :JACC: Heart Failure:…
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation :JACC: Heart Failure: This study and more data being evaluated at FDA circulatory system devices panel : first review via CDRH Breakthrough Device Program
RT @DRDAPO: Cardiac Contractility Modulator shows promising results in RCT. Could be a good option for patient with EF 35-45% with NYHA III…
RT @JACCJournals: New trial (FIX-HF-5) validates safety and effectiveness of cardiac contractility modulation on exercise tolerance & quali…
RT @MCR_CardioRes: Interesting discussion in our Journal Club last week about this new technology for heart failure patients #cardiacdevice…
Interesting discussion in our Journal Club last week about this new technology for heart failure patients #cardiacdevices #CCM
RT @DRDAPO: Cardiac Contractility Modulator shows promising results in RCT. Could be a good option for patient with EF 35-45% with NYHA III…
RT @DRDAPO: Cardiac Contractility Modulator shows promising results in RCT. Could be a good option for patient with EF 35-45% with NYHA III…
RT @DRDAPO: Cardiac Contractility Modulator shows promising results in RCT. Could be a good option for patient with EF 35-45% with NYHA III…
Interesting technology! The field of Cardiac Rhythm Management & Heart continues to evolve. @AAHFN @CEPAupdates @ACSMNews @HeartNurses @AACNme
RT @DRDAPO: Cardiac Contractility Modulator shows promising results in RCT. Could be a good option for patient with EF 35-45% with NYHA III…
Cardiac Contractility Modulator shows promising results in RCT. Could be a good option for patient with EF 35-45% with NYHA III-IV. But how does it compare to CRT for < 35% https://t.co/0veG8SyXYW #JACCHF #ACCFIT #MedEd #CardioTwitter https://t.co/UDKAO
Cardiac Contractility Modulation @impulsedynamics has proven its benefit for mortality and Hf reduction as presented by Prof Perings #Herztage2018 #CCM FIX5HFc study: https://t.co/QOnQlbM6rP https://t.co/OoWnu1ZEZ2
RT @JACCJournals: New trial (FIX-HF-5) validates safety and effectiveness of cardiac contractility modulation on exercise tolerance & quali…
RT @JACCJournals: New trial (FIX-HF-5) validates safety and effectiveness of cardiac contractility modulation on exercise tolerance & quali…
RT @JACCJournals: New trial (FIX-HF-5) validates safety and effectiveness of cardiac contractility modulation on exercise tolerance & quali…
RT @JACCJournals: New trial (FIX-HF-5) validates safety and effectiveness of cardiac contractility modulation on exercise tolerance & quali…
RT @JACCJournals: New trial (FIX-HF-5) validates safety and effectiveness of cardiac contractility modulation on exercise tolerance & quali…
RT @JACCJournals: New trial (FIX-HF-5) validates safety and effectiveness of cardiac contractility modulation on exercise tolerance & quali…
RT @JACCJournals: New trial (FIX-HF-5) validates safety and effectiveness of cardiac contractility modulation on exercise tolerance & quali…
New trial (FIX-HF-5) validates safety and effectiveness of cardiac contractility modulation on exercise tolerance & quality of life in HFrEF. Could this support premarket approval of this novel device by @US_FDA? @TheHeartBeat3 #JACCHF https://t.co/wWQ
RT @ChaudhrySundeep: New therapeutic treatment for heart failure improves peak VO2, symptoms and reduces hospitalizations: https://t.co/lN…
RT @ChaudhrySundeep: New therapeutic treatment for heart failure improves peak VO2, symptoms and reduces hospitalizations: https://t.co/lN…
RT @ChaudhrySundeep: New therapeutic treatment for heart failure improves peak VO2, symptoms and reduces hospitalizations: https://t.co/lN…
New therapeutic treatment for heart failure improves peak VO2, symptoms and reduces hospitalizations: https://t.co/lN7CXiPe7m
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
RT @jvillacastin: Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el…
Se trata de una nueva forma de tratamiento para pacientes en mal grado funcional y con FEVI entre 25 y 45% sin BCRI en el ECG. Se estimula de una forma especial el corazón en periodo refractario y parece mejorar metabolismo cardiaco. https://t.co/y92IsWykS
Simultaneous pub from HRS - device therapies making progress in HF #heartfailure #hfcollaboratory @JACCJournals https://t.co/5ufa9fRZ8H
RT @JACCJournals: New confirmatory trial (FIX-HF-5) presented @ #HRS2018 and published in #JACCHF validating effects of cardiac contractili…
RT @JACCJournals: New confirmatory trial (FIX-HF-5) presented @ #HRS2018 and published in #JACCHF validating effects of cardiac contractili…
RT @mitchelzoler: Confirmatory RCT of cardiac contractility modulation met primary endpoint; CCM now poised (pending FDA approval) to be pl…
RT @mitchelzoler: Confirmatory RCT of cardiac contractility modulation met primary endpoint; CCM now poised (pending FDA approval) to be pl…
Confirmatory RCT of cardiac contractility modulation met primary endpoint; CCM now poised (pending FDA approval) to be placed in tens of thousands of advanced #heartfailure patients who don't qualify for CRT. #HRS2018 https://t.co/MeZBEI8jFy
RT @JACCJournals: New confirmatory trial (FIX-HF-5) presented @ #HRS2018 and published in #JACCHF validating effects of cardiac contractili…
RT @JACCJournals: New confirmatory trial (FIX-HF-5) presented @ #HRS2018 and published in #JACCHF validating effects of cardiac contractili…
RT @JACCJournals: New confirmatory trial (FIX-HF-5) presented @ #HRS2018 and published in #JACCHF validating effects of cardiac contractili…
RT @JACCJournals: New confirmatory trial (FIX-HF-5) presented @ #HRS2018 and published in #JACCHF validating effects of cardiac contractili…
RT @JACCJournals: New confirmatory trial (FIX-HF-5) presented @ #HRS2018 and published in #JACCHF validating effects of cardiac contractili…